These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 39027010)
1. Effectiveness and tolerability of givosiran for the management of acute hepatic porphyria: A monocenter real-life evaluation. Guida CC; Nardella M; Del Mar Ys Perez A; Savino M; Ferrara G; Napolitano F; Crisetti A; Aucella F; Aucella F Mol Genet Metab Rep; 2024 Sep; 40():101111. PubMed ID: 39027010 [TBL] [Abstract][Full Text] [Related]
2. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. Sardh E; Harper P J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial. Kuter DJ; Bonkovsky HL; Monroy S; Ross G; Guillén-Navarro E; Cappellini MD; Minder AE; Hother-Nielsen O; Ventura P; Jia G; Sweetser MT; Thapar M; J Hepatol; 2023 Nov; 79(5):1150-1158. PubMed ID: 37479139 [TBL] [Abstract][Full Text] [Related]
4. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study. Wang B; Ventura P; Takase KI; Thapar M; Cassiman D; Kubisch I; Liu S; Sweetser MT; Balwani M Orphanet J Rare Dis; 2022 Aug; 17(1):327. PubMed ID: 36028858 [TBL] [Abstract][Full Text] [Related]
5. Givosiran for the treatment of acute hepatic porphyria. Ricci A; Ventura P Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E; Liver Int; 2022 Jan; 42(1):161-172. PubMed ID: 34717041 [TBL] [Abstract][Full Text] [Related]
7. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Wang B; Bonkovsky HL; Lim JK; Balwani M Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627 [TBL] [Abstract][Full Text] [Related]
8. Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran. Ventura P; Sardh E; Longo N; Balwani M; Plutzky J; Gouya L; Phillips J; Rhyee S; Fanelli MJ; Sweetser MT; Petrides PE Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):879-894. PubMed ID: 35929959 [TBL] [Abstract][Full Text] [Related]
9. Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria. Graff E; Anderson KE; Levy C Front Genet; 2022; 13():867856. PubMed ID: 35991568 [No Abstract] [Full Text] [Related]
10. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L; N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132 [TBL] [Abstract][Full Text] [Related]
11. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives. Marcacci M; Ricci A; Cuoghi C; Marchini S; Pietrangelo A; Ventura P Orphanet J Rare Dis; 2022 Apr; 17(1):160. PubMed ID: 35392955 [TBL] [Abstract][Full Text] [Related]
15. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693 [TBL] [Abstract][Full Text] [Related]
16. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. Majeed CN; Ma CD; Xiao T; Rudnick S; Bonkovsky HL Drug Des Devel Ther; 2022; 16():1827-1845. PubMed ID: 35734365 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria. Lee J; Melch M; Robbie GJ CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):842-852. PubMed ID: 36883675 [TBL] [Abstract][Full Text] [Related]
18. RNA interference therapy in acute hepatic porphyrias. Yasuda M; Keel S; Balwani M Blood; 2023 Nov; 142(19):1589-1599. PubMed ID: 37027823 [TBL] [Abstract][Full Text] [Related]
19. Givosiran: First Approval. Scott LJ Drugs; 2020 Feb; 80(3):335-339. PubMed ID: 32034693 [TBL] [Abstract][Full Text] [Related]